The estimated Net Worth of Naarden Jacob Van is at least 14.2 百万$ dollars as of 1 February 2024. Mr Van owns over 3,618 units of Lilly(Eli) & Co stock worth over 14,239,722$ and over the last 8 years he sold LLY stock worth over 0$.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr Naarden LLY stock SEC Form 4 insiders trading
Mr has made over 20 trades of the Lilly(Eli) & Co stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 3,618 units of LLY stock worth 3,331,780$ on 1 February 2024.
The largest trade he's ever made was exercising 16,000 units of Lilly(Eli) & Co stock on 10 December 2018 worth over 148,640$. On average, Mr trades about 4,173 units every 84 days since 2016. As of 1 February 2024 he still owns at least 15,463 units of Lilly(Eli) & Co stock.
You can see the complete history of Mr Van stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Jacob S. Van Naarden biography
Jacob S. Van Naarden is the Chief Operating Officer of Loxo Oncology at Lilly(Eli) & Co.
How old is Mr Naarden?
Mr Naarden is 35, he's been the Chief Operating Officer of Loxo Oncology of Lilly(Eli) & Co since . There are 31 older and no younger executives at Lilly(Eli) & Co. The oldest executive at Lilly(Eli) & Co is Kathi Seifert, 71, who is the Independent Director.
What's Mr Naarden's mailing address?
Naarden's mailing address filed with the SEC is Eli Lilly and Company Corporate Center, Indianapolis, Marion County, Indiana, United States.
Insiders trading at Lilly(Eli) & Co
Over the last 20 years, insiders at Lilly(Eli) & Co have traded over 29,994,829,903$ worth of Lilly(Eli) & Co stock and bought 73,808 units worth 5,778,435$ . The most active insiders traders include Endowment Inc Lilly、R David Hoover、Lorenzo Tallarigo. On average, Lilly(Eli) & Co executives and independent directors trade stock every 7 days with the average trade being worth of 55,447,708$. The most recent stock trade was executed by Endowment Inc Lilly on 3 September 2024, trading 24,084 units of LLY stock currently worth 23,281,762$.
What does Lilly(Eli) & Co do?
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.
What does Lilly(Eli) & Co's logo look like?
Complete history of Mr Van stock trades at Lilly(Eli) & Co
Lilly(Eli) & Co executives and stock owners
Lilly(Eli) & Co executives and other stock owners filed with the SEC include:
-
David Ricks,
Chairman of the Board, President, Chief Executive Officer -
Joshua Smiley,
Chief Financial Officer, Senior Vice President -
Daniel Skovronsky,
Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories -
David A. Ricks,
Chairman, CEO & Pres -
Anat Hakim J.D.,
Sr. VP, Gen. Counsel & Sec. -
Jackson Tai,
Independent Director -
Juan Luciano,
Lead Independent Director -
J. Erik Fyrwald,
Independent Director -
Karen Walker,
Independent Director -
William Kaelin,
Independent Director -
Michael Eskew,
Independent Director -
Jamere Jackson,
Independent Director -
Katherine Baicker,
Independent Director -
Raul Alvarez,
Independent Director -
Kathi Seifert,
Independent Director -
Marschall Runge,
Independent Director -
Carolyn Bertozzi,
Independent Director -
Alfonso Zulueta,
Senior Vice President, President - Lilly International -
Ilya Yuffa,
Senior Vice President and President of Lilly Bio-Medicines -
Anne White,
Senior Vice President, President - Lilly Oncology -
Leigh Pusey,
Senior Vice President - Corporate Affairs and Communications -
Myles O'Neill,
Senior Vice President and President - Manufacturing Operations -
Johna Norton,
Senior Vice President - Global Quality -
Michael Mason,
Senior Vice President and President, Lilly Diabetes -
Patrik Jonsson,
Senior Vice President, President of Lilly USA , and Chief Customer Officer -
Stephen Fry,
Senior Vice President - Human Resources and Diversity -
Anat Hakim,
Senior Vice President, General Counsel -
Melissa Barnes,
Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer -
Aarti Shah,
Senior Vice President - Chief Information and Digital Officer -
Leigh Ann Pusey,
Sr. VP of Corp. Affairs & Communications -
Alonzo Weems,
Sr. VP and Chief Ethics & Compliance Officer -
Diogo Rau,
Sr. VP & Chief Information and Digital Officer -
Kevin Hern,
VP of Investor Relations -
Martin Bott MIBS,
VP of Fin. & Special Projects -
Donald A. Zakrowski,
Chief Accounting Officer & VP of Fin. -
Jacob S. Van Naarden,
Chief Operating Officer of Loxo Oncology -
Anat Ashkenazi,
Sr. VP & CFO -
Eric Dozier,
EVP, HR & Diversity -
Endowment Inc Lilly,
-
Christi Shaw,
SVP and Pres., Lilly Bio-Meds -
Fionnuala M Walsh,
SVP, Global Quality -
Jan M Lundberg,
EVP,Science&Tech and Pres. LRL -
Maria A Crowe,
President, Mfg. Operations -
Ralph Alvarez,
Director -
Michael J Harrington,
Senior VP and General Counsel -
Jeffrey N Simmons,
SVP&Pres.,Elanco Animal Health -
Susan Mahony,
SVP, HR & Diversity -
Barton R Peterson,
Sr. VP, Corp. Affairs & Comm. -
Derica W Rice,
Sr. Vice President and CFO -
Enrique A Conterno,
Sr. VP & Pres., Lilly Diabetes -
Naarden Jacob Van,
EVP & Pres., Loxo@Lilly -
Donald A Zakrowski,
SVP, Finance, & CAO -
Karen N Horn,
Director -
John C Lechleiter,
President and COO -
Alonzo Weems,
EVP, ERM & CECO -
R David Hoover,
Director -
Franklyn G Prendergast,
Director -
Ellen R Marram,
Director -
Douglas R Oberhelman,
Director -
Anne Nobles,
Chief Eth/Cmpl Ofcr & SVP, ERM -
Bryce D. Carmine,
EVP and Pres, Lilly Bio-Meds -
Robert A Armitage,
Sr. VP and General Counsel -
Steven M Paul,
EVP, Science and Technology -
Frank M Deane,
President, Manufacturing -
J Michael Cook,
Director -
Alfred G Gilman,
Director -
Martin S Feldstein,
Director -
Sidney Taurel,
Chairman, President and CEO -
Alex M Ii Azar,
Sr. VP, Corp. Affairs & Comm. -
Gino Santini,
Sr.VP, Corp. Strategy & Policy -
Deirdre P Connelly,
President, Lilly USA -
Anthony John Murphy,
Senior VP, Human Resources -
Jacques Tapiero,
SVP&Pres., Emerging Markets -
Winfried F W Sir Bischoff,
Director -
Arnold C Hanish,
Chief Accounting Officer -
Lorenzo Tallarigo,
President, Internat'l Opers. -
George M C Fisher,
Director -
Scott A Canute,
President, Mfg. Operations -
Charles E Golden,
Exec. Vice President and CFO -
Kimberly H Johnson,
Director -
Anat Ashkenazi,
EVP & CFO -
Diogo Rau,
EVP & CIDO -
Edgardo Hernandez,
EVP & Pres., Mfg. Operations -
Gabrielle Sulzberger,
Director -
Mary Lynne Hedley,
Director -
Melissa Seymour,
EVP, Global Quality